New immune combo tackles Hard-to-Treat colorectal cancer
NCT ID NCT07343791
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests a combination of three treatments for advanced colorectal cancer that has not responded to standard therapies. The approach uses the patient's own immune cells (DC-CIK), a targeted drug (regorafenib), and a bispecific antibody to boost the immune system. The study aims to see if this triple therapy can shrink tumors and improve survival in 14 participants.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- DC-CIK cells (immune cells grown from the patient's own blood), regorafenib (a targeted cancer pill), and iparomlimab/tuvonralimab (a bispecific antibody that boosts the immune system)
- What this could lead to
- If it works, this could offer a new third-line treatment option for advanced colorectal cancer, especially for patients whose tumors are not sensitive to standard immunotherapy alone.
- What could go wrong
- This is a very early, small trial (14 people) with no control group. The combination may cause serious side effects, and the benefit may be limited or not confirmed in larger studies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Jinling Hospital
RECRUITINGNanjing, Jiangsu, 210002, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop colon polyps from coming back?
- A stitch in time: could a device make abdominal closure safer?
- Can we predict chemo brain before it happens?
- Your gut bacteria might reveal hidden cancer risk
- Can a smart digital program restore sleep for cancer survivors?
- Can a new infusion drug shrink Hard-to-Treat tumors?